Intercept Pharmaceuticals... (ICPT)
NASDAQ: ICPT
· Real-Time Price · USD
19.00
0.04 (0.21%)
At close: Nov 07, 2023, 10:00 PM
Intercept Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 88.79M | 83.72M | 67.96M | 77.22M | 77.59M | 71.76M | 88.58M | 92.4M | 92.83M | 96.58M | 81.66M |
Cost of Revenue | 197K | 185K | 222K | 29K | 424K | 309K | 758K | 1.01M | 658K | 618K | 810K |
Gross Profit | 88.59M | 83.53M | 67.74M | 77.19M | 77.16M | 71.45M | 87.82M | 91.39M | 92.17M | 95.96M | 80.85M |
Operating Income | -4.62M | -7.12M | -31.63M | -18.91M | -10.14M | -13.36M | -10.27M | -20.87M | -6.22M | 760K | -29.35M |
Interest Income | 1.8M | 2.81M | 2.81M | 3.07M | 5.24M | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -2.76M | -5.83M | -31.88M | -17.54M | -104.09M | -20.32M | -17.28M | -36.28M | -3.63M | -11.09M | -40.42M |
Net Income | -2.79M | -5.86M | -29.57M | -20.38M | 173.51M | -7.53M | -17.28M | -36.28M | -3.63M | -11.09M | -40.42M |
Selling & General & Admin | 45.44M | 53.35M | 57.66M | 55.42M | 43.27M | 39.98M | 50.01M | 60.59M | 53.34M | 57.66M | 59.27M |
Research & Development | 41.51M | 37.31M | 41.71M | 40.68M | 44.03M | 44.83M | 48.09M | 51.67M | 45.05M | 37.79M | 50.77M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | -289K | -339K | -98K | 172K | 735K | n/a |
Operating Expenses | 86.95M | 90.65M | 99.37M | 96.1M | 87.31M | 84.81M | 98.1M | 112.26M | 98.39M | 95.45M | 110.04M |
Interest Expense | 1.55M | 2.81M | 2.81M | 2.81M | 4.6M | 5.87M | 6.67M | 15.32M | 13.46M | 11.9M | 12.42M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 87.15M | 90.84M | 99.59M | 96.13M | 87.73M | 85.12M | 98.85M | 113.27M | 99.05M | 96.06M | 110.85M |
Income Tax Expense | 5.24M | 2.85M | -2.31M | 2.84M | -277.6M | -7.22M | n/a | 14.8M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 41.79M | 41.73M | 41.67M | 41.32M | 34.24M | 29.75M | 29.7M | 29.47M | 31.74M | 33.18M | 33.14M |
Shares Outstanding (Diluted) | 41.79M | 41.73M | 41.67M | 41.48M | 34.29M | 29.75M | 29.7M | 29.54M | 31.74M | 33.18M | 33.14M |
EPS (Basic) | -0.07 | -0.14 | -0.71 | -0.49 | 5.07 | -0.25 | -0.58 | -1.23 | -0.11 | -0.33 | -1.22 |
EPS (Diluted) | -0.07 | -0.14 | -0.71 | -0.49 | 5.06 | -0.25 | -0.58 | -1.23 | -0.11 | -0.33 | -1.22 |
EBITDA | 5.15M | -3.01M | -29.07M | -14.74M | -7.65M | -14.42M | -10.24M | -20.96M | -5.87M | 1.44M | -26.97M |
EBIT | 3.16M | -3.01M | -29.07M | -136.91M | -99.49M | -14.46M | -10.61M | -25.79M | 9.83M | 810K | -28M |
Depreciation & Amortization | 97K | 4.11M | 2.56M | 4.17M | 2.49M | -1.06M | 36K | 421K | 808K | 879K | 870K |